Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yup, that's why the shorts are going to be fighting against the longs to try and manipulate the stock price.
Nice top line results should be coming out soon
Extension and retracement..A B c triangle, 5 counts 9n Elliot wave
Do you use fibonacci extensions?
My guess is shorters trying to freak out investors to panic sell. Looks more likely that investors will buy on the dip.
Correction weekly stochastic 96
I wonder what your crystal ball
is telling us?
FDA rejection or bad phase 3 results? What a drop!
Very true Fmello, i am all for ORMPs success,
although my financial estimates are somewhat
more realistic than yours!
And of course, the BIG question is what will the
mid January resuls show.
Fingers crossed.
GLTU
Thanks Midas.
One of the reasons I am here.
Metformin decreases hepatic glucose production, decreases intestinal
absorption of glucose, and improves insulin sensitivity by increasing
peripheral glucose uptake and utilization.
Insulin, at least up to date doesn't come in pill form because the digestive
system would break it down before it had a chance to work.
(Unlike Metmorfin obviously, which comes in pill)
If ORMP succeeds to prove the possibility that the insulin pill that
does not get destroyed at the liver, this will be considered a huge
success of great magnitude!
In this would be event - this would be a sort of parallel between the two pills.
Moreover if (when) ORMP can show that its unique platform can serve other
meds which are injection taken and transfer to pills, then i can safely say that
ORMP will earn the Noble Prize for this medical achievement
When I read your comment, I think Metformin. I understand they are different animals, but do you see a parallel between Oramed and Metformin?
Well, since we all own the stock, and for all our sakes, I hope I'm the one that's right. ;)
Exactly my p.o.v as expressed:
see #msg-170832610
and #msg-170832717
As a matter of fact, even if positive topline results
with flying colours to be published by mid Jan, i doubt
sp will exceed $20 (for more than a few minutes until
it will simmer down to the $12-15 range level)
Mind you, i hope i am wrong, after all i still hold quite
a lot of shares.
Read the feedback from Korea - that gives real scope of the Oramed tablet scope - it seems it will not be primary method of giving insulin but as add on method and that reduces the revenue potential
If we got FDA approval, I would not be shocked if there was a news story about the big three insulin companies going into a bidding war to buy Oramed.
In 2009, Merck acquired Schering-Plough Corp in order to get their blockbuster skin cancer drug Keytruda. Merck paid 41 BILLION to buy them out. If a big company spent 41 billion to get their hands on Oramed, our stock would be worth over $1,000 per share.
What does anyone think of the possibility of a cash buyout for our shares?
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
https://finance.yahoo.com/news/oramed-granted-u-combination-therapy-125500864.html
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
"With the topline data for our first Phase 3 oral insulin trial expected soon, we continue to further fortify Oramed's leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection," stated Oramed CEO Nadav Kidron.
There is a trick, it worked with my dog. The first few times I tried crushing the meds and place it hiding in their food, they avoid eating their own food, since they tried it the first time with the crushed meds, I guess the bitterness and they can sense the smell. This new trick worked for me, cuddle them first, then when you shove the meds in the mouth and close both jaws and blow air in their nostrils, they have no choice but to swallow it, while gasping for air.
This dog would eat anything put near it's mouth. I'm praying for an oral insulin.
Let's reflect on this. Bullish as phuck.
-- Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023
-- Phase 2 NASH Trial Achieved Primary and Secondary Endpoints
-- Definitive Deal Signed to Commercialize Oral Insulin in South Korea
-- $160 Million in Cash and Investments (as of September 30, 2022)
NEW YORK, Dec. 21, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.
Dear Shareholders and wider investor community,
The year 2022 was a very strong year for Oramed. The first of our two Phase 3 oral insulin trials, ORA-D-013-1, completed enrollment with a wider scope of patients than originally planned, and we expect to announce topline results in mid-January 2023. Concurrently, our Phase 2 NASH trial delivered positive efficacy and safety data. We finished out the third quarter with $160 million in cash and investments with no debt, giving us a long runway through topline results for both of our Phase 3 oral insulin trials and filing for U.S. Food and Drug Administration (FDA) approval of ORMD-0801, potentially the world's first oral insulin capsule to reach the market.
Phase 3 Oral Insulin Trials: Top-Line Data Expected January 2023
ORA-D-013-1, the first of our two pivotal Phase 3 oral insulin trials for ORMD-0801 in the treatment of type 2 diabetes met and exceeded the number of planned participants, with 710 people enrolled. We expect to announce topline results in the next four weeks. ORA-D-013-2, our concurrent Phase 3 trial, continues to enroll the planned 450 patients, with enrollment expected to be completed in 2023.
Phase 2 NASH Trial Achieved Primary Endpoints
Our Phase 2 double-blind, randomized, placebo-controlled, multicenter clinical trial assessing the safety and efficacy of ORMD-0801 in the treatment of non-alcoholic steatohepatitis ("NASH") in 32 patients with Type 2 diabetes and NASH achieved its primary endpoint of safety and tolerability, demonstrating consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. We believe ORMD-0801 may be an ideal treatment option for the millions of people living with both diabetes and NASH. We held a Key Opinion Leader webinar in November discussing the positive data and exciting potential of Oramed's oral insulin candidate as a treatment option for this indication. The full webinar can be viewed on the Oramed website. There is currently no FDA approved treatment for NASH, which is expected to become an $84 billion market by 2029.
Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
Continuing to build global partnerships, we signed an exclusive commercial distribution agreement for South Korea with Medicox Co., Ltd. which will have the exclusive license to apply for regulatory approval and distribute ORMD-0801 for ten years in South Korea. Medicox will purchase ORMD-0801 at an agreed upon transfer price and will additionally pay Oramed up to $18 million in developmental milestones, $2 million of which has already been received by Oramed, and up to 15% royalties on gross sales in a large and growing diabetes market.
Phase 1 Oral COVID-19 Vaccine Trial Reported Positive Preliminary Data
Our subsidiary Oravax's first cohort in its Phase 1 clinical trial of our oral virus-like particle (VLP) COVID-19 vaccine for COVID-naive participants achieved its primary and secondary endpoints of safety and immunogenicity based on preliminary data. Our oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline. We believe this trial shows proof of concept for oral delivery of vaccines using Oravax's technology. Complete Phase 1 results are expected in the first quarter of 2023.
Oral GLP-1 Bioavailability Trial
ORMD-0901, our oral glucagon-like peptide-1 (GLP-1) analog capsule, is currently being evaluated under an FDA Investigational New Drug (IND) application and we expect to issue an update regarding the trial's progress in the coming weeks. GLP-1 is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently available in injectable form only. An oral GLP-1 could significantly increase compliance and become a valuable tool in the treatment of diabetes.
We are entering 2023 with real excitement for what we believe will be a monumental year for the Company. We thank you, our shareholders, for your support and we thank our partners and trial volunteers for helping advance our clinical and other efforts. We wish you all a happy and healthy new year and look forward to keeping all our shareholders updated on news and developments.
Sincerely,
There is always a tomorrow. No one is going to leave this alone with a game changing science that World is waiting for.
Yup. If the markets didn't fall into the red today, we would still be in $13 territory.
This is going to run hard by end of the month. Good luck everyone and Happy New Years.
How hard is it to get a dog to swallow a pill instead of chewing it up first?
My dog gets 2 shots a day. It's about 150.$ per month for insulin and 40ish for needles.
The Global Pet Diabetes Care Market size is expected to reach $2.5 billion by 2028, rising at a market growth of 8.3% CAGR during the forecast period
https://finance.yahoo.com/news/global-pet-diabetes-care-market-112200957.html
That 37% would then translate to 15.17 billion for Ketruda.
Ketruda cannot be compared to Insulin - it is cancer vs diabetes
Also, MRK bought SHERING PLOUGH for $41 B - and at that time Keytruda formed 37% of total revenue
I vaguely remember reading that a Nordic company has been making Oramed's pills currently. The name escapes me though.
When the skin cancer drug Keytruda got positive phase 3 results, Merck bought the company for 41 BILLION! The insulin market is larger than the skin cancer market. If one of the big three insulin companies decided to do the same and buy Oramed for 41 billion, that would translate to a stock price of over a $1,000 per share.
Good find - I had another question -if successful - will ORMP manufacture actual insulin or convert insulin into powder form and pack in tablets?
Current insulin manufacturing is very much controlled by NOVO and LLY and few China and India mfr - so from where they will get the insulin?
On Price side - at current $12 price - the market cap is $480 m - if they prove that they can deliver in tablet form - one of the top insulin co will buy them - the BO price will be between $2.5 to $5 B - so my guesstimate is that ORMP will get 4 to 7 multiplier from current market cap
It would be a gamechanger if we get confirmation from the upcoming results that Oramed's tech work. If the tech is proven to get the payload past the stomach without the strong gastric acids destroying it, then the odds go up that the same tech can safely protect a virus-based vaccine pill like covid or the flu as well.
Also, Oramed can create new revenue streams by licensing their tech to other drug companies that want to get their drugs safely past the stomach as well.
This is going to be the longest two weeks of our lives.
Check out my post on #1577. Dr. Peters brings that up.
This is why Novo's insulin pill failed:
https://www.reuters.com/article/us-novo-nordisk-insulin-pill-idUSKBN13B22I
How about if everyone who takes injectable insulin, will also take the oral to supplement the liver insulin levels? Instead of looking at what percent of the current pie, oral insulin will be for the diabetes market, think of oral insulin as more pie added to the market. It could end up as a valuable supplement to anyone’s diabetes regimen. Possibly preventing future diabetes related health issues.
Vxr+ and €¥+0 are next.
I don't think it's a small market when 537 million people worldwide have diabetes. The IDF predicts 783 million people will have diabetes by 2045. Also, tack on the Nash & vaccine addressable markets after Oramed finishes those trials as well.
https://www.koreabiomed.com/news/articleView.html?idxno=20133
Up 100% now Technical analysis always wins
Repair
Stock accumulation shows great optimism before phase 3
https://stockcharts.com/h-sc/ui?s=ormp&p=D&yr=0&mn=5&dy=0&id=p78146564564
Followers
|
44
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1673
|
Created
|
07/11/06
|
Type
|
Free
|
Moderators |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
1185 Avenue of the Americas
3rd Floor
New York, NY 10036
United States
844 967 2633
http://www.oramed.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |